Table 1.

Characteristics of the studies included in meta-analysis (9 studies included 10 treatment arms)

Study [Ref]	Country of origin	Rando mizatio n	Patients	Enrollme nt period	Total patient s	Age (mean ± SD)		Male/Female		Test for confirming infection	Test for confirming eradication
						Concomitant	Triple	Concomitant	Triple
*Catalano et al 2000 [20]	Italy	RCT	PUD	1/1998- 12/1999	111	41.2±14.2	45.1±12.9	30/26	29/26	RUT & histology	RUT & histology
*Neville et al 1999 [22]	UK	RCT	PUD, NUD & others	NR	112	50.5±15	56±13	21/35	37/19	Culture, RUT, UBT & histology	UBT
*Nagahara et al 2000 [21]	Japan	RCT	PUD & NUD	8/1998 – 5/1999	105	53.8±13.9	52.5±11.9	40/15	34/16	RUT, UBT, histology & HpSA	HpSA
*Treiber et al 1998 [11]	Germany	RCT	PUD & others	NR	88	53.5±15.7	55±17	32/14	28/14	RUT & UBT	RUT, UBT & histology
*Nagahara et al 2001 [23]	Japan	RCT	PUD & NUD	7/1999- 5/2000	160	50±12.1	49.1±12.3	60/20	58/22	RUT, UBT & histology	UBT
Okada et al 1999 [24]	Japan	Non- RCT	PUD & other	6/1997- 5/1998	169	47±14	_	121/48	None	Culture, RUT & histology	Culture, RUT & histology
Calvet et al 2000 [25]	Spain	Non- RCT	PUD	11/1996- 6/1997	56	55.2±16	_	40/16	None	UBT & histology	UBT & histology
‡Treiber et al 2002 L5 [26]	Germany	RCT	PUD, NUD & others	4/1997- 3/1999	83	54.6±14	_	50/33	None	Culture, RUT, UBT, histology & serology	UBT
‡Treiber et al 2002 L3 [26]	Germany	RCT	PUD, NUD & others	4/1997- 3/1999	80	56.5±14	_	47/33	None	Culture, RUT, UBT, histology & serology	UBT
Okada et al 1998 [12]	Japan	Non- RCT	PUD, NUD & others	NR	90	46.2±13.1		70/20	None	Culture, RUT & histology	Culture, RUT, & histology

^*= RCT comparing PPI-concomitant quadruple therapy vs. triple therapy;

^‡=RCT comparing PPI-concomitant quadruple therapy vs. non triple therapy, NUD= Non Ulcer Dyspepsia, PUD= Peptic Ulcer Disease, RUT= Rapid Urease test, UBT= Urea Breath Test, NR= Not Recorded L5 Lansoprazole concomitant quadruple therapy for 5 days , L3= Lansoprazole concomitant quadruple therapy for 3 days.